PATENT CLAIM ANALYSIS

Application Number: 15895894
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "013300"]

Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.

Claim (Index 3):
The pharmaceutical preparation of  claim 1 , wherein the ALK1-Fc fusion protein comprises the amino acid sequence of SEQ ID NO: 3.

Metadata:
- Claim Count in Document: 154.0
- Percentile: 88.0
- Lexical Diversity: 1.52381
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12434598', '13447091', '11982738', '14142094', '12467170']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8993937771380601
- 35 USC 102 Novelty (BERT): 0.7068090757158636
- Combined Prediction Score: 0.8801353069958405
- Mean Citation Score: 802.431426
- Max Citation Score: 863.71063
- Similarity Product: 734.8794257114006

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test